Key facts
- It has raised $2.3M; the latest was Early Stage VC ($2.2M) in Apr 2025.
- Notable investors include Fit 4 Start, Expon Capital, Boryung, Ernst & Young Global, Expansion Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Exobiosphere
- ·The full record, as it builds
Funding rounds
No funding rounds for Exobiosphere are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Exobiosphere
Developer of a space-based research platform designed to accelerate preclinical testing in microgravity conditions. The company's platform offers an automated, space-based testing system that creates disease models in microgravity, enabling pharmaceutical companies to expedite drug development, identify novel targets, and enhance treatment efficacy in various therapeutic areas.
- Sector
- Healthcare
- HQ
- Esch-sur-Alzette, Luxembourg
- Founded
- 2024
- Employees
- 8
- Website
- exobiosphere.com/
- Ownership
- Privately Held (backing)
Exobiosphere doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Exobiosphere shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Exobiosphere in its N-PORT filings yet. We sweep new filings monthly.